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ABSTRACT
The use of antiretrovirals as pre-exposure
prophylaxis (PrEP) is highly efficacious in HIV
prevention. The World Health Organization
recently recommended Truvada (Gilead
Sciences, Inc.) or tenofovir disoproxil fumarate
(TDF) for high-risk individuals, with limited
data for single-agent TDF PrEP in men who have
sex with men (MSM). We report two cases of
TDF PrEP failure in MSM who had received
long-term TDF for hepatitis B infection and had
therapeutic levels of drug immediately after HIV
acquisition. Rapid antiretroviral intensification
at diagnosis of acute HIV infection failed to
limit immune dysfunction or prevent the
establishment of a viral reservoir.
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INTRODUCTION
The use of antiretrovirals (ARVs) as pre-exposure
prophylaxis (PrEP) is highly efficacious at
limiting HIV transmission [1–6]. Recent World
Health Organization (WHO) guidelines
recommend single-agent tenofovir disoproxil
fumarate (TDF) or Truvada [TDF/emtricitabine
(FTC);Gilead Sciences, Inc.] for individuals at risk
of HIV acquisition [7]. Single-agent TDF PrEP
shows benefit over placebo and is comparable
with Truvada in preventing HIV transmission in
HIV serodiscordant heterosexual couples [2] and
individuals who inject drugs [3]. Efficacy data for
TDF in men who have sex with men (MSM) are
limited [8] and it is not knownwhether drug level
requirements are the same for both HIV
treatment and prevention. However, animal
model data suggest that TDF alone is less
protective than Truvada [9, 10] and
pharmacokinetic analysis of the partners PrEP
study supports this [11].
Cases of PrEP failure mainly occur due to
poor adherence [1–6, 11]. Early detection is
essential to minimize monotherapy drug
exposure and prevent drug resistance
development [12]. Whether ARV therapy
(ART) should be stopped or intensified at PrEP
failure is unclear [13]. A recent case presentation
reported an undetectable viral reservoir in an
individual’s intensifying ART at PrEP failure
[14]. This is supported by cohort data and data
from macaques suggest that three-drug ARV at
acute HIV infection can improve clinical
outcome [15–17] by limiting viral reservoir
[17–20] and immune dysfunction [21–23], and
that these benefits are greater the earlier the
ARVs are started [15–17].
We report two cases of PrEP failure amongst
MSM receiving long-term TDF for hepatitis B
treatment with therapeutic tenofovir levels
around the time of HIV-1 acquisition. Despite
continuing TDF and intensifying to
combination ARV at acute HIV diagnosis, both
cases had significant viral reservoirs and
elevated markers of immune activation/
exhaustion within 4 weeks of HIV-1 diagnosis
consistent with established HIV-1 infection.
CASE REPORTS
Patients
Informed consent was obtained from both
patients for being included in this case report.
Two patients from separate HIV centers were
diagnosed with acute HIV whilst receiving TDF
monotherapy for hepatitis B infection. To allow
case comparison, day 1 was defined as the day of
estimated date of HIV seroconversion (EDSC,
i.e., the mid-point date between HIV-negative
and HIV-positive test or 14 days prior to p24
antigen-positive/HIV antibody-negative result).
Both patients had received TDF 300 mg/day
for hepatitis B infection (hepatitis B s-antigen
and e-antigen positive) and maintained a
consistently undetectable hepatitis B DNA for
3? years with no viral blips. In the 6 weeks prior
Fig. 1 Pharmacokinetic plot of tenofovir levels taken at
HIV diagnosis. For patient A the tenofovir trough level
17 h post-dose was 48 ng/mL (between 10th and 25th
centile) and for patient B the tenofovir trough concentra-
tion 7 h post-dose was 220 ng/mL (75th centile). TDF
tenofovir disoproxil fumarate
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to HIV acquisition both individuals reported
condom-less receptive anal sex with casual male
partners and denied any missed doses of TDF.
Longstanding good adherence was further
suggested by the regularity of pharmacy script
provision and drug levels carried out at HIV
diagnosis were within the therapeutic range
(Fig. 1). No other sexually transmitted
infections were detected at HIV diagnosis. ARV
was intensified within 3 weeks of presumed HIV
acquisition and blood taken for quantification
of viral reservoir and immune function
approximately 1 week later. The cases are
summarized in Table 1.
Laboratory Results
PatientAwasdiagnosedwithacuteHIV infection
(HIV antibody positive 10 days after HIV
antibody-negative test and by 3 bands on
Western Blot) following a 4-day history of mild
flu-like symptoms suggestive of seroconversion
illness. Results 9 days after EDSCwere: CD4 T cell
count 584 cells/lL (35%), CD4:CD8 ratio 1.19,
and HIV-1 plasma viral load\50 copies/mL. The
ARV regimen was immediately intensified
(12 days from EDCS) to Eviplera (25 mg
rilpivirine, 200 mg emtricitabine, and 245 mg
TDF; Gilead Sciences International Ltd.) and the
viral load remained undetectable thereafter.
Viral genotype failed to amplify due to low viral
load. Results 15 days after EDSC (3 days after ARV
intensification) showed total HIV-1 DNA
1381 copies/million CD4 cells, integrated DNA
586.6 copies/million CD4 T cells, and unspliced
intracellular HIV-1 RNA transcripts 116 copies/
106 copies 18 s RNA.
Patient B was diagnosed with acute HIV (p24
antigen-positive/antibody-negative antibody)
following hospitalization with a severe
seroconversion illness comprising severe
flu-like symptoms, fatigue, and myalgia.
Results 14 days after EDSC were: CD4 T cell
count 550 cells/lL (24%), CD4:CD8 ratio 0.49,
and HIV-1 plasma viral load 103,306 copies/mL.
The regimen was intensified 19 days after EDSC
to Truvada (one tablet once daily), raltegravir
(400 mg twice daily), darunavir (800 mg once
daily), and ritonavir (100 mg once daily). Viral
genotype showed wild-type drug-sensitive virus.
Blood taken 24 days after EDSC (5 days after
ART intensification) showed total HIV-1 DNA
2746 copies/million CD4 cells, integrated DNA
1431.6 copies/million CD4 T cells, and
unspliced intracellular HIV-1 RNA transcripts
1236 copies/106 copies 18 s RNA.
Immune activation, defined as the
percentage expression of CD38 and HLA-DR
on CD4 and CD8 T cells, was 65.8 and 57% for
patient A and 42.2 and 38.8% for patient B.
METHODS
HIV Diagnosis, Viral Load,
and Therapeutic Drug Level Monitoring
HIV testing was carried out using the Abbott
Architect HIV Ag/Ab combo assay and VIDAS
quantitative HIV p24 11 assay. Confirmation
occurred with Vidas HIV Duo Quick (HIV6)
ELFA fourth-generation assay and Bispot
Immunocomb third-generation assay.
Western blot was carried out using MP
Diagnostics HIV Blot 2.2. HIV-1 plasma viral
load was quantified by Roche COBAS V2.0, and
viral genotype determined using Taqman
sequencing. Tenofovir (TFV) drug levels were
measured by a validated HPLC–MS/MS with a
lower limit of quantification of 5 ng/mL [24].
The tenofovir concentration for each patient
was plotted against a percentile plot derived
from a published population pharmacokinetic
model of tenofovir plasma concentrations in
HIV-infected subjects (Fig. 1) [25].
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Table 1 Summary characteristics of cases of HIV-1 acquisition on TDF
Characteristics Patient A Patient B
Acute HIV diagnosis HIV-positive test 12 days after
HIV-negative test
P24 antigen positive/HIV antibody
negative
Hepatitis B history
Duration known hepatitis B infection 6 years 7 years
Duration TDF monotherapy 4 years 3 years
No. hepatitis B VL blips on TDF 0 0
HIV seroconversion symptoms Mild fever Hospitalized with severe sore throat,
fever
Blood results at acute HIV diagnosis
Days from EDSC to blood test 10 14
HIV VL (copies/mL) \50 158,899
CD4 T cell count 584 (35%) 550 (24%)
CD4:CD8 ratio 1.19 0.49
Hepatitis B VL Undetectable Undetectable
HIV genotype Not possible Wild type
Intensiﬁed ART regime
Days from EDSC to intensiﬁcation 15 19
Regime Eviplera Truvada, raltegravir,
darunavir, ritonavir
Reservoir quantiﬁcation
Days from EDSC to blood test 12 24
HIV total DNA (copies/million
CD4 cells)
1381 (3.14) 2746 (3.44)
Integrated DNA (copies/million
CD4 T cells)
586.6 (2.77) 1431.6 (3.16)
RNA (copies/million CD4 T cells) 116 1236
Immunology
Days from EDSC to blood test 15 24
CD4 ? CD38 ? (%) 65.8 42.2
CD4 ? HLA-DR ? (%) 3.12 4.34
CD8 ? CD38 ? (%) 57 38.8
CD8 ? HLA-DR ? (%) 14.4 9.58
ART antiretroviral therapy, EDSC estimated date of HIV seroconversion, TDF tenofovir disoproxil fumarate, VL viral load
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HIV Reservoir
Purified CD4 T cells were analyzed by qPCR for
HIV-1 DNA (total and integrated) and
cell-associated HIV-1 RNA unspliced transcripts
(CA-RNA) as reported elsewhere [19].
Immune Activation and Exhaustion
PBMC were stained with the anchor markers
(CD3-VioBlue, CD4(VIT4)-VioGreen, CD8-APC)
and a Live/Dead marker Near IR-APC-Cy7 plus
either an activation panel (CD25(3G10)-PE,
CD38-PE-Vio770, CD69-FITC, Anti-HLA-DR-
PerCP) or an exhaustion panel (TIGIT-PE,
TIM-3-FITC, LAG-3-PerCPeF710, PD1-PE-Cy7).
Cells were run on a MACSQuant and analyzed
with FlowJo software v10 (Miltenyi Biotec).
DISCUSSION
As PrEP is becoming more widely available and
uptake increasing, this is a timely reminder that
TDF monotherapy PrEP in MSM has limited
efficacy data and that HIV-1 acquisition can
occur in the presence of TFV drug levels within
the therapeutic range required to treat HIV [26].
These cases are instructive to providers and the
field of PrEP, and highlight that patients with
HBV receiving tenofovir for HBV should
consider intensification to Truvada (TDF/FTC)
if they meet guidelines (e.g., Centers for Disease
Control and Prevention) for PrEP. The lack of
resistance detected concurs with randomized
control study data showing a very low incidence
of resistance in cases of tenofovir failure [29].
Although PrEP effectiveness is largely driven
by adherence [1–8, 11, 26, 27], this was not
implicated in these cases as evidenced by
consistently undetectable hepatitis B DNA and
therapeutic plasma levels of tenofovir at HIV
diagnosis (a proxy for HIV acquisition). Whilst
drug levels were high enough to treat both
hepatitis B and HIV infection [26], the drug
level required to protect from HIV infection is
not known and, if higher, may explain the
transmission events. Additionally, it is not
known whether hepatitis B increases
susceptibility to HIV and the presence of
TDF-resistant mutations may need to be
excluded by minor variant sequencing [12].
These cases also show that rapid
intensification with ARVs did not prevent
reservoir seeding or immune dysfunction.
Indeed, the level of viral reservoir, immune
activation, and immune exhaustion were
comparable to those observed in untreated
primary HIV cohorts [15]. Patient A is of
additional interest as this occurred despite no
evidence of on-going viral replication in plasma
prior to ARV intensification. This suggests the
importance of sanctuary sites for the
establishment of viral reservoir and is
consistent with primate models [27].
CONCLUSION
Single-drug TDF PrEP was not effective in
preventing HIV infection and intensified ART
post-infection did not reduce the viral reservoir
in either patient. Whilst single-agent PrEP is not
to be recommended as an HIV prevention
strategy in MSM in European [28] and US [13]
PrEP guidelines, it is by the WHO [7]. Close
monitoring of outcomes of TDF usage in MSM
needs to be carried out.
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